Peptides Under PCAC Review Before the End of February 2027: What Each Outcome Means

By Peptide Ecommerce · August 10, 2026

FDA will hold a Pharmacy Compounding Advisory Committee meeting before the end of February 2027 on whether 5 bulk drug substances, among them GHK-Cu and Melanotan II, belong on the 503A bulks list, and the committee's recommendations are nonbinding, so the outcome that counts is the decision FDA makes afterward (FDA). For what FDA has already done, our warning letter tracker lists 11 warning letters that name a peptide product or a research use only peptide sale, 5 of them dated August 24, 2026.

For your research-use-only peptide storefront, the PCAC review calendar provides a planning reference for product selection and inventory exposure. FDA intends to publish a Federal Register notice and establish a docket for public comment on this meeting. Further docket details become available when that notice publishes.

Key Facts

FDA plans to hold the upcoming PCAC review before the end of February 2027 (FDA).
FDA intends to make meeting materials and the live webcast link available no later than two business days before the meeting (FDA).
FDA retains full regulatory decision-making authority over matters considered by PCAC (FDA).
FDA finalizes 503A bulk substance additions through notice-and-comment rulemaking (FDA).

TL;DR

Interested persons may present data, information or views on issues pending before PCAC.
FDA intends to publish a Federal Register notice and establish a docket for public comment on the upcoming PCAC review (FDA).
PCAC reviews scientific, technical, and medical issues concerning compounding under sections 503A and 503B (FDA).
FDA evaluates intended use from labeling claims, advertising matter, oral or written statements and the circumstances of distribution (U.S. Code of Federal Regulations, hosted by Cornell Legal Information Institute).

What the PCAC Review Cycle Is

The PCAC evaluates substances for potential inclusion on the 503A bulks list, which governs what licensed compounding pharmacies may use as bulk drug substances. In prepared remarks from 2024, then FDA Commissioner Robert M. Califf described advisory committees as “a vital resource in helping us as we evaluate complicated issues.” The review cycle has three possible outcomes for each substance considered:

A favorable review means PCAC recommends a substance for inclusion on the 503A bulks list. FDA retains full regulatory decision-making authority over matters considered by PCAC. The public can comment after FDA publishes a proposed rule. FDA considers those comments before publishing a final rule.

An unfavorable review means PCAC recommends against including a substance on the 503A bulks list. FDA retains full regulatory decision-making authority over matters considered by PCAC (FDA).

A deferred review leaves the substance pending further consideration. FDA convenes PCAC as needed under applicable legal and regulatory authorities (FDA). Meeting frequency varies with the issues presented for committee advice.

Review timing is set by FDA. On its Pharmacy Compounding Advisory Committee meeting page, FDA states that it will host an advisory committee meeting before the end of February 2027, and it has published the agenda of bulk drug substances the committee will discuss for potential inclusion on the 503A bulks list. FDA has not yet published the docket for that meeting. Its stated position is that it intends to publish a Federal Register notice and establish a docket for public comment in the near future, and that more information regarding the docket becomes available once that notice publishes. So the agenda is fixed, the exact date and the comment docket are not, and the Federal Register notice is the event to watch. FDA intends to make meeting materials and the live webcast link available no later than two business days before the meeting. The meeting also includes an open public hearing session where interested persons may request a slot to present data, information or views on issues pending before PCAC.

Peptides Named for PCAC Review Before the End of February 2027

FDA has published the agenda for this meeting on its Pharmacy Compounding Advisory Committee meeting page. The committee will discuss five bulk drug substances being considered for inclusion on the 503A bulks list, and FDA lists them as Cathelicidin (LL-37), GHK-Cu, Dihexa acetate, Melanotan II, and Mechano Growth Factor Pegylated (PEG-MGF). The published agenda names all five substances. The discussion below summarizes each substance and what the PCAC review means for RUO operators overall.

GHK-Cu (copper peptide tripeptide-1): GHK-Cu is used in research applications including studies of wound healing biology, cellular growth factors, and skin tissue biology at the research level. For GHK-Cu, a favorable recommendation supports inclusion on the 503A bulks list, while an unfavorable recommendation opposes inclusion. The potential compounding-pharmacy market depends on FDA's regulatory action and compliance with applicable section 503A conditions. FDA evaluates intended use from labeling claims, advertising matter, oral or written statements and the circumstances of distribution (U.S. Code of Federal Regulations, hosted by Cornell Legal Information Institute).

Melanotan II: Melanotan II is a synthetic analog of alpha-melanocyte-stimulating hormone researched in studies related to melanocortin receptor biology. FDA issued a warning letter to Melanocorp concerning Melanotan II in 2007 (FDA). A future PCAC recommendation concerns its proposed inclusion on the 503A bulks list. FDA evaluates intended use from labeling claims, advertising matter, oral or written statements and the circumstances of distribution.

LL-37 (cathelicidin antimicrobial peptide): LL-37 is a naturally occurring human antimicrobial peptide studied in immunology and microbiology research contexts. Its use in research is established. PCAC will consider LL-37 for inclusion on the 503A bulks list. FDA retains full regulatory decision-making authority over matters considered by PCAC. FDA evaluates intended use from labeling claims, advertising matter, oral or written statements and the circumstances of distribution (U.S. Code of Federal Regulations, hosted by Cornell Legal Information Institute).

Dihexa acetate: Dihexa is a peptide researched in neuroscience contexts, particularly in studies related to angiotensin IV receptor binding. It is a less widely carried substance in the current RUO market. The PCAC review is a planning input that signals possible change: a favorable review signals movement toward potential compoundability, while an unfavorable review signals the current trajectory is constrained, and either way compounding eligibility changes only when FDA takes its own later action on the 503A bulks list.

PEG-MGF (pegylated mechano growth factor): PEG-MGF is a modified form of mechano growth factor (MGF), itself an isoform of insulin-like growth factor 1 (IGF-1). Research use of PEG-MGF involves studies of muscle and tissue biology at the cellular level. The pegylation modification affects pharmacokinetic properties studied in research settings. PEG-MGF is one of the five substances under PCAC review, and the review's outcome for PEG-MGF signals whether its regulatory trajectory becomes more or less constrained.

What "Unfavorable" Means for a Substance You Currently Carry

PCAC reviews scientific, technical, and medical issues concerning compounding under sections 503A and 503B. Its remit also extends, as required, to other products under FDA's regulatory responsibility. For this meeting, PCAC's task is to advise on the five substances' inclusion on the 503A bulks list. FDA retains full regulatory decision-making authority over matters considered by PCAC (FDA). FDA evaluates intended use from labeling claims, advertising matter, oral or written statements and the circumstances of distribution.

An unfavorable recommendation records PCAC's assessment of a substance for the 503A bulks list (FDA). Your inventory exposure can be assessed against the committee's stated concerns, existing FDA actions, and whether the substance has been nominated for the 503A bulks list.

A compliance review can examine your inventory concentration, COA records, product labeling, marketing material, and customer communications. FDA evaluates intended use from labeling claims, advertising matter, oral or written statements and the circumstances of distribution (U.S. Code of Federal Regulations, hosted by Cornell Legal Information Institute).

Anticipatory Positioning: How to Think About Product Lineup Decisions

The PCAC review calendar gives RUO operators a planning signal. It functions as a probability input for regulatory trajectory.

For substances with upcoming unfavorable review risk, the positioning question is: what is my inventory concentration, and what is my exposure if this substance's regulatory trajectory becomes more constrained over the next 12 to 24 months? This is a business risk question.

For substances with upcoming favorable review, the question is different: a favorable review may eventually increase demand from compounding pharmacies if a final rule is issued, which could affect the supply market. FDA controls the timeline from a favorable review to rulemaking to a final rule, independent of the committee vote.

What stays in force: Product claims, marketing language, and customer communications remain subject to FDA's intended-use framework during advisory review. FDA evaluates intended use from labeling claims, advertising matter, oral or written statements and the circumstances of distribution (U.S. Code of Federal Regulations, hosted by Cornell Legal Information Institute).

Do not accelerate inventory in a substance based on a favorable review outcome. The downstream rulemaking process is uncertain in both timing and outcome.

The PCAC review is a planning input that signals possible change for a substance carried in inventory. Only FDA's later action on the 503A bulks list changes what licensed compounding pharmacies may use as bulk drug substances, so the operator bases product decisions on that action. Related guide: What the PCAC Vote Changes for Your Peptide Store: The Correct Answer.

What to Watch For

Three events form the monitoring sequence. First, FDA intends to publish a Federal Register notice and establish a docket for public comment on this meeting. The notice provides meeting details and public-participation procedures. Second, FDA intends to make meeting materials and the live webcast link available no later than two business days before the meeting. Third, PCAC's meeting records document its deliberations and recommendations, followed by FDA's regulatory decisions and any proposed rulemaking (FDA). The rulemaking announcement in the Federal Register is the event that would actually begin a process that could change the 503A bulks list. Interested persons may present data, information or views on issues pending before PCAC.

For the complete catalog of research peptides currently available for your storefront and their current regulatory status context, see the product reference at /30-peptides.html.

Frequently Asked Questions

How can you contribute to the PCAC meeting?

Interested persons may present data, information or views on issues pending before PCAC. You can request a presentation slot for the open public hearing.

How does FDA handle public comments during list development?

The public can comment after FDA publishes a proposed rule. FDA considers those comments before publishing a final rule.

Who sets the frequency of PCAC meetings?

FDA convenes PCAC as needed under applicable legal and regulatory authorities. Meeting frequency varies with the issues presented for committee advice.

Sources

Considering outside help? Questions to ask before choosing a peptide business coach